Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer Diagnosis
Open Access
- 1 January 2022
- journal article
- research article
- Published by SAGE Publications in Biomarker Insights
- Vol. 17
Abstract
Clinical management of gynecological cancer begins by optimal debulking with first-line platinum-based chemotherapy. However, in ~80% patients, ovarian cancer will recur and is lethal. Prognostic gene signature panel identifying platinum-resistance enables better patient stratification for precision therapy. Retrospectively collected serum from 11 “poor” (24 months PFI) prognosis patients, were evaluated using circulating cell-free DNA (cfDNA). DNA from both groups showed 50 to 10 000 bp fragments. Pairwise analysis of sequenced cfDNA from patients showed that gene dosages were higher for 29 genes and lower for 64 genes in poor than favorable prognosis patients. Gene ontology analysis of higher dose genes predominantly grouped into cytoskeletal proteins, while lower dose genes, as hydrolases and receptors. Higher dosage genes searched for cancer-relatedness in Reactome database indicated 15 genes were referenced with cancer. Among them 3 genes, TGFBR2, ZMIZ2, and NRG2, were interacting with more than 4 cancer-associated genes. Protein expression analysis of tumor samples indicated that TGFBR2 was downregulated and ZMIZ2 was upregulated in poor prognosis patients. Our results indicate that the cfDNA gene dosage combined with protein expression in tumor samples can serve as gene signature panel for prognosis determination amongst ovarian cancer patients.Keywords
This publication has 81 references indexed in Scilit:
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Fold change and p-value cutoffs significantly alter microarray interpretationsBMC Bioinformatics, 2012
- Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumorsGynecologic Oncology, 2011
- Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancersAnnals of Oncology, 2010
- Plasma cell‐free DNA in ovarian cancerCancer, 2010
- A Novel Role for Protein Inhibitor of Activated STAT (PIAS) Proteins in Modulating the Activity of Zimp7, a Novel PIAS-like Protein, in Androgen Receptor-mediated TranscriptionJournal of Biological Chemistry, 2010
- How do real tumors become resistant to cisplatin?Cell Cycle, 2008
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences, 2001